Homocysteine-Lowering Therapy and Risk for Venous Thromboembolism

  1. Joel G. Ray, MD, MSc;
  2. Clive Kearon, MD, PhD;
  3. Qilong Yi, PhD;
  4. Patrick Sheridan, MSc;
  5. Eva Lonn, MD, MSc; and
  6. for the Heart Outcomes Prevention Evaluation 2 (HOPE-2) Investigators*
  1. From St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada, and the Population Health Research Institute, Hamilton General Hospital, McMaster University, Hamilton, Ontario, Canada.
    1. Figure 1. *Limited to the 3306 participants for whom homocysteine was measured at baseline. †Homocysteine level >13.8 µmol/L.
      View larger version:
      Figure 1. *Limited to the 3306 participants for whom homocysteine was measured at baseline. †Homocysteine level >13.8 µmol/L. Risk for venous thromboembolism (VTE) in prespecified subgroups.
    2. Figure 2.
      View larger version:
      Figure 2. Cumulative proportion of participants with venous thromboembolism.

    Responses to this article

    • In Response
      • Mandeep S Dhami
      Ann Intern Med published online October 26, 2009
    • Question to Authors
      • Lynn A Bentson
      Ann Intern Med published online October 26, 2009
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med June 5, 2007 vol. 146 no. 11 761-767
    1. AbstractFREE
    2. » Figures
    3. Full Text
    4. Full Text (PDF)

    Current Issue

    1. November 3, 2009, 151 (9)
    1. Alert me to current issues